58 completed, 22 recruiting, 16 terminated, 11 not yet recruiting. 71 Phase 2, 44 Phase 1, 17 Phase 3, 2 Not applicable, 1 Early Phase 1.
Follow Primary Peritoneal Cancer: new trials by email Literature Review of Primary Peritoneal Cancer trials Research Report on Primary Peritoneal Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer Trastuzumab Rezetecan (SHR-A1811), Bevacizumab, Platinum-based chemotherapy - Ovarian Cancer, Fallopian Tube Cancers | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 53 | 2026-10-22 | 2026-10-01 |
| Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic Lesions Routine-care metastasis-directed radiotherapy - Cervical Cancer, Gynecologic Cancer | Recruiting | Affidea Nu-med Center of Oncological DIagnostics and Therapy | 500 | 2026-10-06 | 2026-10-20 | |
| A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03) R-DXd, Bevacizumab - Fallopian Tube Cancer, Primary Peritoneal Cancer | Phase 3 | Not yet recruiting | Daiichi Sankyo | 600 | 2026-10-01 | 2026-09-01 |
| Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers BG-C9074, Bevacizumab - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Not yet recruiting | BeOne Medicines | 600 | 2026-10-01 | 2026-09-10 |
| Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin Standard of Care + atorvastatin, Standard of Care (SOC) - Ovarian Cancer, Fallopian Tube Cancers | Phase 2 | Not yet recruiting | University of Colorado, Denver | 40 | 2026-09-01 | 2026-09-11 |
| A Real-world Study of Mirvetuximab Soravtansine (MIRV) in Ovarian Cancer Patients of Expression of Folate Receptor α（FRα） Mirvetuximab Soravtansine (MIRV) - Ovarian Cancer, Fallopian Tube Cancers | Not yet recruiting | NING LI-GYN | 400 | 2026-07-20 | 2026-07-24 | |
| A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer BL-M07D1, Liposomal Doxorubicin, Paclitaxel - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 404 | 2026-07-01 | 2026-06-29 |
| Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer Reirradiation, Total Ablative Strategy - Recurrent Gynecologic Cancer, Recurrent Uterine Cancer | Recruiting | Affidea Nu-med Center of Oncological DIagnostics and Therapy | 500 | 2026-06-11 | 2026-10-16 | |
| Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer Liposomal Irinotecan - Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancers | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 30 | 2026-05-30 | 2026-05-18 |
| Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal Cancer Benmelstobart in combination with Anlotinib and oral metronomic Cyclophosphamide - Ovarian Cancer, Fallopian Tube Cancers | Phase 2 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 40 | 2026-03-30 | 2026-03-24 |
| Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer Aitua Combination Antibody, Albumin-Bound Paclitaxel /nab-Paclitaxel, Carboplatin (AUC 5) - High-grade Serous Ovarian Cancer (HGSOC), Fallopian Tube Cancers | Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 82 | 2026-03-01 | 2026-02-25 |
| Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors Romiplostim N01, All-trans retinoic acid - Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia | Phase 2 | Recruiting | Peking University People's Hospital | 220 | 2025-12-22 | 2026-05-14 |
| CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer TORL-1-23 and paclitaxel, TORL-1-23 and carboplatin, TORL-1-23, paclitaxel, and carboplatin - FIGO Stage III and IV Ovarian Cancer, Fallopian Tube Cancers | Phase 1 / Phase 2 | Recruiting | TORL Biotherapeutics, LLC | 60 | 2025-12-10 | 2026-07-13 |
| Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer Cirtuvivint, Olaparib - Endometrioid Ovarian Cancer, Primary Peritoneal Cancer | Phase 1 | Recruiting | University of Colorado, Denver | 50 | 2025-12-08 | 2026-07-24 |
| A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. Carboplatin, Mirvetuximab Soravtansine, Bevacizumab - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Recruiting | AbbVie | 140 | 2025-11-21 | 2026-10-20 |
| Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Utidelone capsule 75mg/m2/d QD, Utidelone capsule 40mg/m2/d BID, Utidelone capsule 50mg/m2/d BID - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Not yet recruiting | Beijing Biostar Pharmaceuticals Co., Ltd. | 72 | 2025-09-01 | 2025-06-30 |
| A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) BL-B01D1, Liposomal doxorubicin, Paclitaxel or Topotecan - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 450 | 2025-08-04 | 2026-07-07 |
| PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer PARP inhibitor + Bevacizumab, PARP inhibitor - Ovarian Cancer, Fallopian Tube Cancers | Phase 2 / Phase 3 | Recruiting | N.N. Alexandrov National Cancer Centre | 120 | 2025-07-01 | 2026-03-16 |
| Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer Ubamatamab, Bevacizumab, Cemiplimab - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Recruiting | Regeneron Pharmaceuticals | 297 | 2025-05-28 | 2026-09-14 |
| A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine Mirvetuximab Soravtansine - Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer | Phase 2 | Recruiting | AbbVie | 110 | 2025-05-28 | 2026-05-26 |
Showing 20 of 124. Sign in to see all of them.
Fallopian Tube Neoplasms (106) · Ovarian Neoplasms (88) · Carcinoma, Ovarian Epithelial (32) · Breast Neoplasms (9) · Endometrial Neoplasms (8) · Recurrence (8) · Neoplasms (7) · Carcinoma, Renal Cell (5) · Colorectal Neoplasms (5) · Uterine Cervical Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Melanoma (4) · Kidney Neoplasms (3) · Neoplasm Metastasis (3) · Stomach Neoplasms (3)
Adnexal Diseases (118) · Female Urogenital Diseases (118) · Female Urogenital Diseases and Pregnancy Complications (118) · Genital Diseases (118) · Genital Diseases, Female (118) · Genital Neoplasms, Female (118) · Neoplasms by Site (118) · Urogenital Diseases (118) · Urogenital Neoplasms (118) · Neoplasms (111) · Endocrine Gland Neoplasms (108) · Endocrine System Diseases (108) · Gonadal Disorders (108) · Ovarian Diseases (108) · Fallopian Tube Diseases (106)
Bevacizumab (27) · Paclitaxel (27) · Carboplatin (20) · Gemcitabine (9) · liposomal doxorubicin (8) · Cisplatin (6) · mirvetuximab soravtansine (6) · pembrolizumab (6) · Cyclophosphamide (5) · Topotecan (5) · niraparib (5) · Albumin-Bound Paclitaxel (4) · Interleukin-2 (4) · Nivolumab (4) · trebananib (4)
National Cancer Institute (NCI) (6) · AbbVie (4) · Amgen (4) · Eli Lilly and Company (4) · Memorial Sloan Kettering Cancer Center (4) · Abramson Cancer Center at Penn Medicine (3) · Dana-Farber Cancer Institute (3) · Imunon (3) · M.D. Anderson Cancer Center (3) · University Health Network, Toronto (3) · Affidea Nu-med Center of Oncological DIagnostics and Therapy (2) · Grupo Español de Investigación en Cáncer de Ovario (2) · Masonic Cancer Center, University of Minnesota (2) · Massachusetts General Hospital (2) · Merck Sharp & Dohme LLC (2)
United States (69) · Canada (17) · Belgium (14) · Spain (14) · China (13) · Australia (12) · United Kingdom (11) · South Korea (10) · France (9) · Germany (8) · Poland (8) · Italy (6) · Japan (6) · Austria (4) · Brazil (4)
Stephanie Lheureux, M.D. (2) · Alessandro D. Santin, MD (1) · Alexi A Wright, MD, MPH (1) · Alfonso Yubero, Dr. (1) · Alice Chen, M.D. (1) · Alice P Chen, M.D. (1) · Amar Patel, MD (1) · Amir A. Jazaeri, MD (1)
PMID 37185961, PMID 36608308, PMID 37407274, PMID 19767092, PMID 22044606, PMID 23032745, PMID 23948349, PMID 24356636, PMID 24777970, PMID 25037684, PMID 25070546, PMID 25462205, PMID 25589624, PMID 26026738, PMID 26745694, PMID 27029706, PMID 28453702, PMID 28497258, PMID 30792217, PMID 31791552, PMID 31826802, PMID 32747013, PMID 33278077, PMID 33327047, PMID 33470063, PMID 34210826, PMID 34686353, PMID 34920291, PMID 35149854, PMID 35170751, PMID 36706655, PMID 36718624, PMID 37082579, PMID 37227734, PMID 37334673, PMID 37666539, PMID 37735588, PMID 38010394, PMID 38872480, PMID 39058367, PMID 39251349, PMID 39516558, PMID 40382284, PMID 40461366, PMID 40700855, PMID 40974837, PMID 41175449, PMID 41928160
2009 (2), 2023 (2), 2016 (1), 2025 (1), R01CA288651 (1), R01CA289547 (1)